Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
University of Pennsylvania, Medical Devices Deals, 2011 to YTD 2017 12
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
University of Pennsylvania, Pharmaceuticals & Healthcare, Deal Details 16
Partnerships 16
Incyte Enters into Research Agreement with Abramson Cancer Center 16
Tempus Health Enters into Agreement with Penn Medicine 17
Liquid Biotech Enters into Research Agreement with University of Pennsylvania 18
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 19
Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 20
Biogen Enters into Co-Development Agreement with University of Pennsylvania 21
Seres Therapeutics Enters into Agreement with University of Pennsylvania 22
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 23
Genisphere Enters into Research Agreement with University of Pennsylvania 24
NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 25
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 26
Janssen Pharma Enters into Agreement with University of Pennsylvania 27
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 28
Epic Sciences Partners with Abramson Cancer Center 29
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 30
PTC Therapeutics Enters into Agreement with University of Pennsylvania 31
CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 32
Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 33
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 34
PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 35
Licensing Agreements 36
Expres2ion Biotech Enters into Licensing Agreement with University of Pennsylvania 36
Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 37
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 38
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 39
Cetazam Therapeutics Enters into Licensing Agreement with Perelman School of Medicine 40
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 41
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 43
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 44
Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 45
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 46
Novartis Enters Into Licensing Agreement With University of Pennsylvania For CART-19 47
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 49
Advaxis Enters Into Licensing Agreement With University of Pennsylvania For ISG15 50
Atrin Pharmaceuticals Enters into Licensing Agreement with University of Pennsylvania 51
Equity Offering 52
Tmunity Therapeutics Raises USD10 Million in Equity Financing 52
Asset Transactions 53
University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For US$55 Million 53
Acquisition 54
University of Pennsylvania Health System To Acquire Chester County Hospital 54
University of Pennsylvania – Key Competitors 55
University of Pennsylvania – Key Employees 56
University of Pennsylvania – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Recent Developments 58
Government and Public Interest 58
Sep 27, 2017: Melanoma Cells Rewire Their Signaling Pathways to Resist Drug Treatment 58
Sep 26, 2017: PCORI Board approves $8.6 million for study on treatment options for psoriasis and $2.75 million for research on atrial fibrillation 59
Jul 18, 2017: New Combination of Anti-obesity Drugs may have Beneficial Effects 60
Jun 26, 2017: CRI Announces $1 Million Technology Impact Award Recipient 61
May 18, 2017: Researchers connect brain blood vessel lesions to intestinal bacteria 62
Feb 24, 2017: Penn Vet Team Identifies New Therapeutic Targets for the Tropical Disease Leishmaniasis 64
Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients 66
Sep 30, 2016: Penn Scientists Receive $24 Million from National Science Foundation to Establish MechanoBiology Center 68
Aug 02, 2016: Cancer checkpoint drug target governs metabolic changes in exhausted T cells 69
Jul 28, 2016: Bayer Recognizes Research in Hemophilia and Bleeding Disorders for Fourteenth Straight Year 70
Jul 25, 2016: Scientists Test Ways to Discuss Opioid Risks With ER Patients 71
Jul 13, 2016: The Wistar Institute and Partners Receive Nearly $23 Million from NIH to Advance HIV Cure Research 72
Jun 21, 2016: New CAR T cell therapy using double target aimed at solid tumors 73
May 27, 2016: Identifying How Merkel Cell Polyomavirus Infection can Cause a Lethal Carcinoma 74
May 25, 2016: International, Multi-Institutional, Women-Led Research Team Receives $900,000 Research Grant from L’Oréal Paris USA and Melanoma Research Alliance to Study Metastatic Melanoma 75
Apr 07, 2016: Helmsley Charitable Trust Awards $2.1 Million to Penn, Stanford and Seattle Children’s Research Institute to Explore Cell-Based Therapies for Type 1 Diabetes 77
Mar 30, 2016: Naltrexone is alternative treatment for opioid addiction, Penn-led study finds 78
Mar 28, 2016: Structure of Parkinson’s protein could lead to new diagnostic and treatment options 79
Mar 18, 2016: Penn Researchers Show Rising Opioid Prescriptions Following Low-Risk Surgeries 80
Mar 17, 2016: Treating HIV patients at risk for tuberculosis with TB drugs doesn’t save more lives 81
Mar 15, 2016: Study Suggests Reduced Immunosuppression Drug Dose May Be Best for Kidney Transplant Outcomes 82
Feb 18, 2016: Penn research: An FDA-approved Alzheimer’s drug could help smokers quit 83
Product News 85
Nov 30, 2016: Penn Scientists Use CRISPR for First Time to Correct Clotting in Newborn and Adult Mice 85
Aug 02, 2016: Penn Researchers Improve Computer Modeling for Designing Drug-delivery Nanocarriers 86
Jul 20, 2016: Penn-led team develops plant-based Polio booster vaccine 87
Jun 30, 2016: New therapy treats autoimmune disease without harming normal immunity 89
Other Significant Developments 91
Oct 27, 2016: Janssen Partners with University of Pennsylvania and Castleman Disease Collaborative Network to Launch First Global Patient Registry for Castleman Disease 91
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92
University of Pennsylvania, Pharmaceuticals & Healthcare, Key Facts, 2015 2
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University of Pennsylvania, Deals By Therapy Area, 2011 to YTD 2017 10
University of Pennsylvania, Medical Devices Deals, 2011 to YTD 2017 12
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Incyte Enters into Research Agreement with Abramson Cancer Center 16
Tempus Health Enters into Agreement with Penn Medicine 17
Liquid Biotech Enters into Research Agreement with University of Pennsylvania 18
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 19
Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 20
Biogen Enters into Co-Development Agreement with University of Pennsylvania 21
Seres Therapeutics Enters into Agreement with University of Pennsylvania 22
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 23
Genisphere Enters into Research Agreement with University of Pennsylvania 24
NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 25
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 26
Janssen Pharma Enters into Agreement with University of Pennsylvania 27
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 28
Epic Sciences Partners with Abramson Cancer Center 29
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 30
PTC Therapeutics Enters into Agreement with University of Pennsylvania 31
CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 32
Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 33
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 34
PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 35
Expres2ion Biotech Enters into Licensing Agreement with University of Pennsylvania 36
Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 37
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 38
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 39
Cetazam Therapeutics Enters into Licensing Agreement with Perelman School of Medicine 40
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 41
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 43
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 44
Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 45
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 46
Novartis Enters Into Licensing Agreement With University of Pennsylvania For CART-19 47
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 49
Advaxis Enters Into Licensing Agreement With University of Pennsylvania For ISG15 50
Atrin Pharmaceuticals Enters into Licensing Agreement with University of Pennsylvania 51
Tmunity Therapeutics Raises USD10 Million in Equity Financing 52
University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For US$55 Million 53
University of Pennsylvania Health System To Acquire Chester County Hospital 54
University of Pennsylvania, Key Competitors 55
University of Pennsylvania, Key Employees 56
University of Pennsylvania, Subsidiaries 57
